Art. -Nr.: HY-13662

Lansoprazole

(Synonyms: AG-1749)

5 Cited Publications

Kundenbewertung

Based on 5 publication(s) in Google Scholar

Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 103577-45-3
Formel: C₁₆H₁₄F₃N₃O₂S
Molecular Weight:369.36

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Lansoprazole Chemical Structure

CAS. Nr.: 103577-45-3

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (5)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Phospholipase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
AGS	IC₅₀	149 μM Compound: Lansoprazole	Cytotoxic activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human AGS cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26009162]
AGS	IC₅₀	162 μM Compound: Lansoprazole	Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay Cytotoxicity against human AGS cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
BXPC-3	IC₅₀	124 μM Compound: lansoprazole	Inhibition of FASN in human BxPC3 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting Inhibition of FASN in human BxPC3 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting	[PMID: 25513712]
BXPC-3	IC₅₀	6.71 μM Compound: lansoprazole	Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay Inhibition of survival of human BxPC3 cells after 10 to 14 days by crystal violet staining-based colony formation assay	[PMID: 25513712]
Caco-2	IC₅₀	62.8 μM Compound: Lansoprazole	TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 5 uM) in Caco-2 cells	[PMID: 11770010]
Fibroblast	IC₅₀	291 μM Compound: Lansoprazole	Cytotoxic activity against human fibroblasts assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxic activity against human fibroblasts assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 26009162]
HEK-293T	IC₅₀	24.38 μM Compound: Lansoprazole	Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis Inhibition of recombinant human C-MYC/DDK-tagged ENGase expressed in HEK293T cells using heat inactivated bovine ribonuclease B as substrate pretreated for 15 mins followed by substrate addition after 90 mins by SDS-PAGE analysis	[PMID: 28512024]
HEK-293T	IC₅₀	8.2 μM Compound: Lansoprazole	Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido2 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HEK-293T	IC₅₀	94 μM Compound: Lansoprazole	Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis Inhibition of mouse Ido1 transfected in HEK293T cells using L-tryptophan as substrate assessed as kynurenine formation after 45 mins by spectrophotometric analysis	[PMID: 23122865]
HepG2	IC₅₀	221 μM Compound: Lansoprazole	Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human HepG2 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
HUVEC	GI₅₀	>100 μM Compound: Lansoprazole	Cytotoxicity against HUVEC cells Cytotoxicity against HUVEC cells	[PMID: 31923859]
K562	GI₅₀	>100 μM Compound: Lansoprazole	Antiproliferative activity against human K562 cells harboring MLL1 Antiproliferative activity against human K562 cells harboring MLL1	[PMID: 31923859]
L02	GI₅₀	>100 μM Compound: Lansoprazole	Cytotoxicity against human L02 cells Cytotoxicity against human L02 cells	[PMID: 31923859]
MOLM-13	GI₅₀	30.1 μM Compound: Lansoprazole	Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9 Antiproliferative activity against human MOLM-13 cells harboring MLL1-AF9	[PMID: 31923859]
MRC5	IC₅₀	306 μM Compound: Lansoprazole	Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay Cytotoxicity against human MRC5 cells after 24 hrs by neutral red uptake assay	[PMID: 20359186]
MV4-11	GI₅₀	21.1 μM Compound: Lansoprazole	Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4 Antiproliferative activity against human MV4-11 cells harboring MLL1-AF4	[PMID: 31923859]
PANC-1	IC₅₀	93 μM Compound: lansoprazole	Inhibition of FASN in human PANC1 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting Inhibition of FASN in human PANC1 cells assessed as inhibition of [14C]acetate incorporation preincubated for 4 hrs before [14C]acetate addition measured after 2 hrs by scintillation counting	[PMID: 25513712]

In Vitro

Lansoprazole from 0.3 to 3 μM inhibits gastric acid formation in a concentration-dependent manner (IC₅₀ of 0.76 μM)^[4].
Lansoprazole (30-300 μM) both induced concentration-dependent, reversible and reproducible relaxations of arteries^[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Lansoprazole (20-40 mg/kg) treatment significantly attenuated STZ and HFD -induced memory deficits, biochemical and histopathological alterations^[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced increase in AChE activity^[3].
Lansoprazole (20 mg/kg and 40 mg/kg, p.o.) significantly reduces the STZ and HFD- induced rise in brain MPO level^[3].
Further HFD mice treated with lansoprazole (20 mg/kg and 40 mg/kg, p.o.) shows a marked decrease in the body weight in comparison to the control animals^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Swiss albino mice (20–25 g) of either sex^[3].
Dosage:

20 mg/kg, 40 mg/kg.
Administration:

PO, started after second dose of STZ and then subjected to MWM test. Continued (30 min before) during the acquisition trial conducted from day 1 to day 4.
Result:

Significantly attenuated the day 4 rise in ELT and decreased in day 5 TSTQ in the STZ as well as HFD treated mice in a dose dependent manner.

Chemical Information

CAS. Nr. 103577-45-3
Appearance Solid
Molecular Weight 369.36
Formel C₁₆H₁₄F₃N₃O₂S
Color White to off-white
SMILES

O=S(C1=NC2=CC=CC=C2N1)CC3=NC=CC(OCC(F)(F)F)=C3C
Synonyms

AG-1749
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (5)

All Bio/Physico-chemical Assay

Sort by:

Journal Impact Factor

Nat Commun

Sequence-based drug design as a concept in computational drug design. [Abstract]

2023 Jul 14;14(1):4217. PMID: 37452028
J Med Chem

Mechanism of CRM1 Inhibition by Lansoprazole and Its Synergy with Cisplatin in Gastric Cancer. [Abstract]

2026 May 28;69(10):11705-11719. PMID: 42134807
FASEB J

Lansoprazole Enhances Everolimus Efficacy Through DDIT3-Mediated PI3K/AKT/mTOR Pathway Inhibition in Pancreatic Neuroendocrine Neoplasms Proliferation. [Abstract]

2026 Apr 15;40(7):e71722. PMID: 41911054
Results Chem

2024 Oct.

Lansoprazole purchased from MedChemExpress. Usage Cited in: Results Chem. 2024 Oct.

Zero-order absorption spectra of 5.0 µg/mL (LEV, RAB, LAN (Lansoprazole), PAR, and AMO).

Lansoprazole purchased from MedChemExpress. Usage Cited in: Results Chem. 2024 Oct.

Determination of LEV, RAB, Lansoprazole (LAN), PAR, and AMO in the pharmaceutical formulation by chemometric techniques and application of the standard addition technique.
Sci Rep

Cysteine-reactive mitigators of small vessel disease-related NOTCH3 mutants. [Abstract]

2026 Mar 20;16(1):14300. PMID: 41862552

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 100 mg/mL (270.74 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 10 mg/mL (27.07 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7074 mL

13.5369 mL

27.0739 mL

5 mM

0.5415 mL

2.7074 mL

5.4148 mL

10 mM

0.2707 mL

1.3537 mL

2.7074 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (6.77 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (275 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Kokufu, T., et al., Effects of lansoprazole on pharmacokinetics and metabolism of theophylline. Eur J Clin Pharmacol, 1995. 48(5): p. 391-5. [Content Brief]

[2]. Huarui Zhang, et al. Advances in the discovery of exosome inhibitors in cancer. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1322-1330. [Content Brief]

[3]. Rupinder K Sodhi, et al. Defensive effect of lansoprazole in dementia of AD type in mice exposed to streptozotocin and cholesterol enriched diet. PLoS One. 2013 Jul 31;8(7):e70487. [Content Brief]

[4]. Jun Matsukawa, et al. A comparative study on the modes of action of TAK-438, a novel potassium-competitive acid blocker, and lansoprazole in primary cultured rabbit gastric glands. Biochem Pharmacol. 2011 May 1;81(9):1145-51. [Content Brief]

[5]. Erdinc Naseri, et al. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries. Eur J Pharmacol. 2006 Feb 15;531(1-3):226-31. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	2.7074 mL	13.5369 mL	27.0739 mL	67.6846 mL
	5 mM	0.5415 mL	2.7074 mL	5.4148 mL	13.5369 mL
	10 mM	0.2707 mL	1.3537 mL	2.7074 mL	6.7685 mL
	15 mM	0.1805 mL	0.9025 mL	1.8049 mL	4.5123 mL
	20 mM	0.1354 mL	0.6768 mL	1.3537 mL	3.3842 mL
	25 mM	0.1083 mL	0.5415 mL	1.0830 mL	2.7074 mL
DMSO	30 mM	0.0902 mL	0.4512 mL	0.9025 mL	2.2562 mL
	40 mM	0.0677 mL	0.3384 mL	0.6768 mL	1.6921 mL
	50 mM	0.0541 mL	0.2707 mL	0.5415 mL	1.3537 mL
	60 mM	0.0451 mL	0.2256 mL	0.4512 mL	1.1281 mL
	80 mM	0.0338 mL	0.1692 mL	0.3384 mL	0.8461 mL
	100 mM	0.0271 mL	0.1354 mL	0.2707 mL	0.6768 mL

Lansoprazole

5 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Lansoprazole

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

FDA-Approved Drug Library

Anti-Cancer Compound Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Anti-COVID-19 Compound Library

NMPA-Approved Drug Library

Cytoskeleton Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Exosomes Compound Library

Drug-Induced Liver Injury (DILI) Compound Library

Lipid Metabolism Compound Library

Rare Diseases Drug Library

FDA-Approved Anticancer Drug Library

Human Metabolite Library

Anti-Pulmonary Fibrosis Compound Library

Off-patent Drug Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Extracellular Vesicles (EVs) Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Nephrotoxicity Compound Library

RNA Binding Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) Lansoprazole

Alle Phospholipase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (5)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Lansoprazole Related Classifications

HY-13662 Related Classifications